Stay updated on Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial

Sign up to get notified when there's something new on the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The clinical trial record for nivolumab and cabiralizumab in resectable biliary tract cancer is displayed, with study details and its withdrawn status indicating that no subjects were enrolled.
    Difference
    43%
    Check dated 2026-11-08T11:39:41.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study record remains unavailable and displays a 403 error.
    Difference
    0.2%
    Check dated 2026-11-01T12:30:03.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A banner was added announcing NIH website transition updates and noting that NIH content may use “Super Intelligence” alongside “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T12:36:20.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page continues to display a 403 Forbidden error. Its footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T12:19:37.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer revision marker changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T13:43:21.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page instead of the study record, with the standard header and footer shown and no study content accessible. This indicates access to the original content is blocked.
    Difference
    17%
    Check dated 2026-09-20T10:36:49.000Z thumbnail image

Stay in the know with updates to Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page.